Point72 Hong Kong Ltd Takes Position in Insulet Co. (NASDAQ:PODD)

Point72 Hong Kong Ltd purchased a new stake in shares of Insulet Co. (NASDAQ:PODD) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 2,332 shares of the medical instruments supplier’s stock, valued at approximately $278,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in PODD. Janus Henderson Group PLC raised its stake in shares of Insulet by 4.9% during the second quarter. Janus Henderson Group PLC now owns 369,611 shares of the medical instruments supplier’s stock valued at $44,124,000 after purchasing an additional 17,328 shares in the last quarter. Jennison Associates LLC raised its stake in shares of Insulet by 53.6% during the second quarter. Jennison Associates LLC now owns 283,817 shares of the medical instruments supplier’s stock valued at $33,882,000 after purchasing an additional 98,995 shares in the last quarter. Swiss National Bank raised its stake in shares of Insulet by 2.4% during the second quarter. Swiss National Bank now owns 110,300 shares of the medical instruments supplier’s stock valued at $13,168,000 after purchasing an additional 2,600 shares in the last quarter. Columbus Circle Investors raised its stake in shares of Insulet by 74.6% during the second quarter. Columbus Circle Investors now owns 165,863 shares of the medical instruments supplier’s stock valued at $19,801,000 after purchasing an additional 70,860 shares in the last quarter. Finally, First Hawaiian Bank raised its stake in shares of Insulet by 2,758.3% during the second quarter. First Hawaiian Bank now owns 1,715 shares of the medical instruments supplier’s stock valued at $205,000 after purchasing an additional 1,655 shares in the last quarter.

NASDAQ PODD traded up $6.03 on Tuesday, hitting $164.53. 43,466 shares of the company were exchanged, compared to its average volume of 1,228,911. The company’s 50 day moving average price is $150.20 and its 200-day moving average price is $116.86. The company has a debt-to-equity ratio of 2.43, a current ratio of 4.72 and a quick ratio of 3.91. The firm has a market capitalization of $9.39 billion, a P/E ratio of 3,289.80 and a beta of 1.00. Insulet Co. has a twelve month low of $70.80 and a twelve month high of $168.00.



Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Monday, August 5th. The medical instruments supplier reported $0.02 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.03 by ($0.01). The company had revenue of $177.10 million for the quarter, compared to analyst estimates of $163.63 million. Insulet had a return on equity of 7.85% and a net margin of 2.66%. Insulet’s quarterly revenue was up 42.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.03) EPS. As a group, equities analysts expect that Insulet Co. will post 0.25 EPS for the current year.

A number of equities research analysts recently weighed in on the stock. Jefferies Financial Group lifted their price objective on shares of Insulet from $105.00 to $140.00 and gave the company a “buy” rating in a research note on Tuesday, August 6th. Northland Securities cut shares of Insulet from an “outperform” rating to a “market perform” rating and set a $100.00 price target on the stock. in a research report on Monday, June 10th. BidaskClub upgraded shares of Insulet from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 13th. UBS Group boosted their price target on shares of Insulet from $110.00 to $130.00 and gave the stock a “buy” rating in a research report on Thursday, June 13th. Finally, Guggenheim boosted their price target on shares of Insulet from $100.00 to $145.00 and gave the stock a “positive” rating in a research report on Tuesday, August 6th. Four investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $140.93.

In other Insulet news, CEO Shacey Petrovic sold 649 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $152.40, for a total transaction of $98,907.60. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Michael P. Spears sold 4,153 shares of the business’s stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $146.12, for a total value of $606,836.36. Following the sale, the senior vice president now owns 22,626 shares in the company, valued at approximately $3,306,111.12. The disclosure for this sale can be found here. 3.50% of the stock is currently owned by insiders.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.

Read More: How can you know how many shares are floating?

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Co. (NASDAQ:PODD).

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.